San Francisco, CA – November 11, 2024 – VeriSIM Life, a pioneer in AI-driven drug development, is thrilled to announce it has won a Gold Stevie® Award for Most Innovative Company of the Year in the Stevie Awards for Women in Business. The Stevie Awards are widely recognized as the premier business accolades worldwide, celebrating the outstanding achievements of women leaders, entrepreneurs, and companies they lead. Dr. Jo Varshney founded VeriSIM Life in 2017 to transform the drug development landscape, and this honor reflects the company’s commitment to bringing life-saving therapies to patients more efficiently.
This year, the Stevie Awards received over 1,500 entries from organizations across 36 countries, evaluated by a distinguished panel of more than 200 global business professionals. VeriSIM Life's Gold award underscores the groundbreaking impact of its BIOiSIM platform, which addresses the "translational gap" in drug development by guiding researchers on where to focus experiments and investments. This innovation accelerates the drug development process, reducing costs and timelines to an unprecedented degree. BIOiSIM has enabled industry giants such as Mayo Clinic, Debiopharm, and Daiichi-Sankyo to advance drug candidates from early research to clinical trials significantly faster than traditional methods allow.
VeriSIM Life's portfolio includes six drug assets currently under development, led by PT001, a promising treatment for pulmonary arterial hypertension. Achieving pre-IND status in under three years, PT001 exemplifies the platform’s capability to expedite drug development—an industry milestone in a field where this phase typically takes six years or more. The BIOiSIM platform’s capabilities span therapeutic areas, including oncology, substance use disorders, and rare diseases, positioning VeriSIM Life as a pivotal partner in groundbreaking drug development.
“It’s an immense honor to have our team recognized for leading innovation in life sciences, and we celebrate alongside the other winners,” says Dr. Varshney. “This Gold Stevie Award affirms our dedication to revolutionizing drug development and our mission to deliver critical therapies to patients faster than ever.”
Gold, Silver, and Bronze Stevie Award winners were announced during a gala event at the Marriott Marquis Hotel in New York City on Friday, November 8.
About VeriSIM Life
VeriSIM Life has developed BIOiSIM®, an advanced computational platform that harnesses AI and machine learning to transform drug discovery and development. As a first-in-class virtual drug development engine, BIOiSIM delivers exceptional value to the industry by quickly identifying drug candidates with the highest potential for treating or curing specific diseases. The platform predicts clinical trial success rates early in the preclinical stage, enabling developers to focus on the most viable options. By reducing unnecessary experiments and guiding critical program decisions, BIOiSIM significantly cuts down on time and cost, accelerating the path from discovery to market for life-saving therapies. For more information, visit www.verisimlife.com.
About The Stevie Awards
Stevie Awards are conferred in nine programs: the Asia-Pacific Stevie Awards, the German Stevie Awards, The American Business Awards®, The International Business Awards®, the Middle East & North Africa Stevie Awards, the Stevie Awards for Women in Business, the Stevie Awards for Great Employers, the Stevie Awards for Sales & Customer Service, and the Stevie Awards for Technology Excellence. Stevie Awards competitions receive more than 12,000 nominations each year from organizations in more than 70 nations and territories. Honoring organizations of all types and sizes and the people behind them, the Stevies recognize outstanding performances in the workplace worldwide. Learn more about the Stevie Awards at www.StevieAwards.com.
AtlasGEN Novel Drug Designer efficiently identifies new molecules based on favorable chemical properties and simultaneously evaluates them for clinical safety and effectiveness based on biology using VeriSIM Life’s groundbreaking Translational Index™ technology.
Iterative ranking of target engaging hits by their Translational Index values reduces the time and cost associated with other computational hit discovery approaches, while compressing the hit-to-lead refinement and optimization process by pre-validating hits for translatability. This unique integration dramatically reduces the number of compounds to evaluate in subsequent experimental research.
The ability to generate target engaging compound hits depends largely on the size of the molecular search library. The AtlasGEN search space is supported by more than 1 trillion compounds. Generative AI and deep learning techniques deliver unprecedented discovery capability.
AtlasGEN accurately predicts protein-lygand binding affinity by combining geometric conformer analysis with machine learning based on experimental data 72% more efficiently than molecular docking-based approaches.
.png)
